These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 8352552)

  • 1. A preliminary pharmacokinetic evaluation of the antimetastatic immunomodulator swainsonine: clinical and toxic implications.
    Bowen D; Adir J; White SL; Bowen CD; Matsumoto K; Olden K
    Anticancer Res; 1993; 13(4):841-4. PubMed ID: 8352552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction of swainsonine with lymphoid and highly perfused tissues: a pharmacokinetics explanation for sustained immunomodulation.
    Bowen D; Southerland WM; Bowen CD; Hughes DE
    Anticancer Res; 1997; 17(6D):4345-6. PubMed ID: 9494531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of subacute swainsonine (locoweed; Oxytropis sericea) consumption on immunocompetence and serum constituents of sheep in a nutrient-restricted state.
    Taylor JB; Strickland J; May T; Hawkins DE
    Vet Hum Toxicol; 2000 Aug; 42(4):199-204. PubMed ID: 10928681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of 9-methoxy-N,N-dimethyl-5-nitropyrazolo [3,4, 5-kl]acridine-2(6H)-propanamine (PZA, PD 115934, NSC 366140) in mice: guidelines for early clinical trials1.
    Foster BJ; Wiegand RA; LoRusso PM; Baker LH
    Clin Cancer Res; 1995 Aug; 1(8):831-7. PubMed ID: 9816052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coadministration of swainsonine and doxorubicin attenuates doxorubicin-induced lethality in mice.
    Oredipe OA; Furbert-Harris PM; Laniyan I; Green WR; Griffin WM; Sridhar R
    Cell Mol Biol (Noisy-le-grand); 2003 Nov; 49(7):1037-48. PubMed ID: 14682385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical pharmacology of the natural product anticancer agent bryostatin 1, an activator of protein kinase C.
    Zhang X; Zhang R; Zhao H; Cai H; Gush KA; Kerr RG; Pettit GR; Kraft AS
    Cancer Res; 1996 Feb; 56(4):802-8. PubMed ID: 8631017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1996 Aug; 383():1-370. PubMed ID: 12692653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and metabolism of a novel antifibrotic drug pirfenidone, in mice following intravenous administration.
    Giri SN; Wang Q; Xie Y; Lango J; Morin D; Margolin SB; Buckpitt AR
    Biopharm Drug Dispos; 2002 Jul; 23(5):203-11. PubMed ID: 12116052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
    Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
    Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is the volume of distribution of digoxin reduced in patients with renal dysfunction? Determining digoxin pharmacokinetics by fluorescence polarization immunoassay.
    Cheng JW; Charland SL; Shaw LM; Kobrin S; Goldfarb S; Stanek EJ; Spinler SA
    Pharmacotherapy; 1997; 17(3):584-90. PubMed ID: 9165563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interconversion and tissue distribution of pentoxifylline and lisofylline in mice.
    Wyska E; Pekala E; Szymura-Oleksiak J
    Chirality; 2006 Aug; 18(8):644-51. PubMed ID: 16721727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue and serum swainsonine concentrations in sheep ingesting Astragalus lentiginosus (locoweed).
    Stegelmeier BL; James LF; Panter KE; Molyneux RJ
    Vet Hum Toxicol; 1995 Aug; 37(4):336-9. PubMed ID: 8540223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunological evaluation of SW-HSA conjugate on goats.
    Tong D; Mu P; Dong Q; Zhao B; Liu W; Zhao J; Li L; Zhou T; Wang J; Sui G
    Colloids Surf B Biointerfaces; 2007 Jul; 58(1):61-7. PubMed ID: 17126535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bcl-2, after intravenous administration or continuous subcutaneous infusion to mice.
    Raynaud FI; Orr RM; Goddard PM; Lacey HA; Lancashire H; Judson IR; Beck T; Bryan B; Cotter FE
    J Pharmacol Exp Ther; 1997 Apr; 281(1):420-7. PubMed ID: 9103525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of the new thyrotropin releasing hormone analogue montirelin hydrate. 2nd communication: distribution and transfer into the fetus and milk after a single intravenous administration and pharmacokinetics and enzyme induction after repeated intravenous administration to rats.
    Sugimoto T; Hayashi T; Okita A; Morino A
    Arzneimittelforschung; 1996 Feb; 46(2):114-27. PubMed ID: 8720299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic studies in mice of two new thioxanthenones (183577 and 232759) that showed preferential solid tumor activity.
    Foster BJ; Wiegand RA; Pugh S; LoRusso PM; Rake J; Corbett TH
    Clin Cancer Res; 1997 Nov; 3(11):2047-53. PubMed ID: 9815596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carbonoyloxy analogs of the anti-metastatic drug swainsonine. Activation in tumor cells by esterases.
    Dennis JW; White SL; Freer AM; Dime D
    Biochem Pharmacol; 1993 Oct; 46(8):1459-66. PubMed ID: 8240396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mice primed with swainsonine are protected against doxorubicin-induced lethality.
    Oredipe OA; Furbert-Harris PM; Laniyan I; Green WR; Griffin WM; Sridhar R
    Cell Mol Biol (Noisy-le-grand); 2003 Nov; 49(7):1089-99. PubMed ID: 14682391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mathematical comparison between volume of distribution (V) and volume of distribution at steady-state (Vss) utilizing model-independent approach.
    Sobol E; Bialer M
    Biopharm Drug Dispos; 2004 Mar; 25(2):99-101. PubMed ID: 14872558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic evaluation of LASSBio-579: an N-phenylpiperazine antipsychotic prototype.
    Conrado DJ; Verli H; Neves G; Fraga CA; Barreiro EJ; Rates SM; Dalla Costa T
    J Pharm Pharmacol; 2008 Jun; 60(6):699-707. PubMed ID: 18498705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.